What it's for (Indications)
- Clarithromycin is a macrolide antibiotic prescribed for a broad spectrum of bacterial infections.
- Its primary indications encompass acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, acute maxillary sinusitis, pharyngitis and tonsillitis, and uncomplicated skin and skin structure infections caused by susceptible organisms.
- Furthermore, it is a crucial component of multi-drug regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease, typically in combination with a proton pump inhibitor and another antibiotic.
- Clarithromycin also plays a vital role in the treatment and prophylaxis of disseminated mycobacterial infections, particularly those caused by Mycobacterium avium complex (MAC), in immunocompromised patients, including those with advanced HIV infection.
- The precise indication, dosage, and duration of therapy depend on the specific pathogen identified, the site of infection, and the patient's clinical status and renal function, as determined by a healthcare professional.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of clarithromycin is highly dependent on the specific infection being treated, its severity, and the patient's renal function. For most common bacterial infections in adults, the typical oral dosage of immediate-release clarithromycin is 250 mg to 500 mg every 12 hours for 7 to 14 days. Extended-release formulations are available, usually administered as 500 mg to 1000 mg once daily for 7 to 14 days, depending on the indication. In the context of Helicobacter pylori eradication, clarithromycin is often given at 500 mg twice daily as part of a triple therapy regimen, usually for 10 to 14 days. For Mycobacterium avium complex infections, doses can range from 500 mg twice daily. Dosage adjustments are mandatory for patients with significant renal impairment (creatinine clearance less than 30 mL/min) to prevent accumulation and potential toxicity; typically, the dose should be halved or the dosing interval extended. Pediatric dosages are weight-based and should follow specific guidelines for pediatric populations. |
Safety & Warnings
Common Side Effects
- Clarithromycin is generally well-tolerated, but like all medications, it can cause a range of side effects.
- Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal pain, and dyspepsia.
- A notable and unique side effect is taste perversion (dysgeusia), often described as a metallic or bitter taste, which usually resolves upon discontinuation of the drug.
- Less common but more serious side effects include hepatotoxicity, characterized by elevated liver enzymes, cholestatic or hepatocellular hepatitis, which can rarely progress to liver failure.
- Cardiovascular effects, such as QT interval prolongation and the risk of Torsades de Pointes, particularly in susceptible individuals, are also a significant concern.
- Hypersensitivity reactions, ranging from rash and urticaria to severe conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported.
- Other potential side effects include headache, dizziness, insomnia, and in rare cases, Clostridium difficile-associated diarrhea (CDAD), which can range from mild to life-threatening colitis.
- Patients should promptly report any severe or persistent side effects to their healthcare provider.
Serious Warnings
- Black Box Warning: Clarithromycin does not carry a formal FDA Black Box Warning. However, based on significant safety concerns identified through clinical trials and post-marketing surveillance, particularly concerning cardiovascular mortality and severe drug interactions, the following serious warnings are critically important for healthcare professionals and patients: **Serious Warnings:** 1. **Increased Risk of Cardiovascular Mortality:** A meta-analysis of randomized, controlled clinical trials evaluating clarithromycin in adult patients with coronary artery disease (CAD) observed an increased risk of cardiovascular death in those receiving clarithromycin, particularly when followed for up to several years after exposure. The magnitude and mechanism of this risk are not fully elucidated, but it underscores the need for careful consideration of the overall benefit-risk profile when prescribing clarithromycin, especially in patients with pre-existing cardiac conditions. Prescribers should weigh this risk against the potential benefits, particularly in long-term use scenarios or in patients with underlying cardiac vulnerability. 2. **Serious Drug Interactions:** Clarithromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with medications primarily metabolized by CYP3A4 can lead to significantly increased systemic exposure of these drugs, resulting in potentially severe or life-threatening adverse reactions. This includes, but is not limited to, HMG-CoA reductase inhibitors (e.g., lovastatin, simvastatin) which can cause severe myopathy, including rhabdomyolysis, and colchicine, which can lead to fatal colchicine toxicity, particularly in patients with renal or hepatic impairment. Close monitoring, dose adjustments, or complete avoidance of concomitant use are essential for drugs such as warfarin, oral hypoglycemics, certain benzodiazepines, and various other medications that are CYP3A4 substrates. 3. **QT Prolongation and Torsades de Pointes:** Clarithromycin has been associated with prolongation of the QT interval and cases of Torsades de Pointes, a potentially fatal ventricular arrhythmia. This risk is heightened in patients with pre-existing QT prolongation, uncorrected electrolyte imbalances (hypokalemia, hypomagnesemia), clinically significant bradycardia, or who are concurrently receiving other drugs known to prolong the QT interval (e.g., antiarrhythmics, antipsychotics). Use with extreme caution in these high-risk populations, and consider alternative antibiotics if possible, especially when co-administered with other QT-prolonging agents. 4. **Hepatotoxicity:** Cases of hepatic dysfunction, ranging from mild elevations in liver enzymes to severe cholestatic, hepatocellular, or mixed hepatitis, with or without jaundice, have been reported with clarithromycin use. In rare instances, this has progressed to liver failure, some of which have been fatal. Patients should be monitored for signs and symptoms of hepatotoxicity, and the drug should be discontinued immediately if liver injury is suspected or if abnormal liver function tests persist or worsen.
- Several significant warnings are associated with clarithromycin use.
- Patients with pre-existing cardiac conditions, particularly those with a history of QT prolongation, uncorrected hypokalemia or hypomagnesemia, or significant bradycardia, are at an increased risk of developing ventricular arrhythmias, including Torsades de Pointes.
- Caution is advised when prescribing clarithromycin to patients concurrently receiving other medications known to prolong the QT interval.
- Hepatic dysfunction, ranging from transient enzyme elevations to severe hepatotoxicity and liver failure, has been reported; therefore, clarithromycin should be used with caution in patients with hepatic impairment and liver function should be monitored.
- Clostridium difficile-associated diarrhea (CDAD) can occur with nearly all antibacterial agents, including clarithromycin, and its severity can range from mild diarrhea to fatal colitis; careful assessment is required if diarrhea occurs post-treatment.
- Discontinuation of clarithromycin should be considered if CDAD is suspected or confirmed.
- Exacerbation of myasthenia gravis has also been reported in patients receiving macrolides, including clarithromycin, necessitating close monitoring for muscle weakness.
How it Works (Mechanism of Action)
Clarithromycin exerts its antibacterial effect by inhibiting bacterial protein synthesis. It achieves this by reversibly binding to the 50S ribosomal subunit of susceptible bacteria. This binding action effectively blocks the translocation step in the protein synthesis pathway, thereby preventing the elongation of the nascent peptide chain and the assembly of new proteins. By halting protein production, clarithromycin ultimately inhibits bacterial growth and replication, rendering it primarily bacteriostatic. However, at higher concentrations or against highly susceptible organisms, it can exhibit bactericidal activity. This mechanism of action is characteristic of the macrolide class of antibiotics, distinguishing it from other antibiotic families that target cell wall synthesis or nucleic acid replication. The drug's efficacy relies on its ability to penetrate bacterial cells and achieve adequate intracellular concentrations at the site of ribosomal action to interfere with bacterial protein synthesis effectively.